Jefferies Financial Group Inc. Acquires New Position in GlycoMimetics, Inc. (NASDAQ:GLYC)

Jefferies Financial Group Inc. bought a new position in shares of GlycoMimetics, Inc. (NASDAQ:GLYC) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 423,777 shares of the biotechnology company’s stock, valued at approximately $106,000. Jefferies Financial Group Inc. owned 0.66% of GlycoMimetics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caxton Corp purchased a new stake in shares of GlycoMimetics in the fourth quarter worth $51,000. ADAR1 Capital Management LLC boosted its holdings in GlycoMimetics by 626.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock worth $83,000 after buying an additional 286,127 shares during the period. Wellington Management Group LLP purchased a new stake in GlycoMimetics in the 4th quarter worth $352,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in GlycoMimetics during the fourth quarter valued at about $1,268,000. Institutional investors own 75.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GLYC. StockNews.com assumed coverage on GlycoMimetics in a research note on Saturday. They issued a “sell” rating for the company. Cantor Fitzgerald initiated coverage on GlycoMimetics in a report on Friday, March 21st. They issued an “overweight” rating on the stock.

GlycoMimetics Stock Performance

GLYC opened at $0.25 on Monday. The stock has a market capitalization of $15.94 million, a price-to-earnings ratio of -0.54 and a beta of 1.70. The company has a fifty day moving average of $0.24 and a 200 day moving average of $0.27. GlycoMimetics, Inc. has a fifty-two week low of $0.14 and a fifty-two week high of $0.63.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. On average, equities research analysts forecast that GlycoMimetics, Inc. will post -0.08 earnings per share for the current year.

About GlycoMimetics

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.